The file's text, extracted by GovTribe without its formatting.
Summary-FFP Attachment G2 - Firm Fixed Price Sheet Template
Summary
| Price |
| Objective 1 - Labor (FFP) | $ |
| Objective 1 - ODCs | $ |
| TOTAL: | $ |
| Objective 2 - Labor (FFP) | $ |
| Objective 2 - ODCs | $ |
| TOTAL: | $ |
| Objective 3 - Labor (FFP) | $ |
| Objective 3 - ODCs | $ |
| TOTAL: | $ |
| Price |
| Labor | $ |
| ODCs | $ |
| Total Government Project Price | $ |
Objective Summary-FFP
Objectives 1 - 3
| Price Category | Objective 1 | Objective 2 | Objective 3 | Total |
| PRIME LABOR | $ - 0 | $ - 0 | $ - 0 | $ |
| ODCs - CONSULTANT(S) | - 0 | - 0 | - 0 | $ |
| ODCs - MATERIALS & SUPPLIES | - 0 | - 0 | - 0 | $ |
| ODCs - GENERAL | - 0 | - 0 | - 0 | $ |
| ODCs -TRAVEL | - 0 | - 0 | - 0 | $ |
| ODCs - SUBCONTRACTOR(S) | - 0 | - 0 | - 0 | $ |
Totals $ $ $ $
Milestones Cost-FFP
Objective 1 - 3
| Milestones | | | | | |
| Milestone No. | SOW Objective No. | SOW Task No. | Significant Event / Accomplishments | Due Date | FFP |
| M1 | Obj 1 | 11.1 | XXXXXXXXX | 15-Feb-27 | $X |
Total Milestone Price $
Objective 1-FFP
| OBJECTIVE 1 - 24 MONTHS | | | | | |
| ( 1-12 Months ) | | | | | |
| Labor Position(s) | | | | | |
| Sult, Christopher M CIV USARMY USAMRAA (USA): Labor for the Prime Performer only. | Labor Hours | No of FTEs | Hourly Rate | Total Hourly Rate | | |
| Example: Scientist | | 1,980 | 1 | $50.00 | |
| 1374798916: Propose in US Dollars and round to the the hundreth decimal place in every cell. | $99,000.00 | | | | | |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| TOTAL | | 1980 | 1 | N/A | $ 99,000.00 |
| Other Direct Costs (ODCs) | | | |
| ODCs | Quantity | Price ($) | Total |
| Example: Subcontractor (ABC Inc.) | N/A | $1,000,000.00 | $1,050,000.00 |
| Example: Consultant (Sarah Smith) | 31 hrs | $10,850.00 | $11,393.00 |
| Example: Travel/Trip #1 | 1 | $3,500.00 | $3,675.00 |
| Example: Travel/Trip #2 | 1 | $2,000.00 | $2,100.00 |
| | $0.00 | $0.00 |
| | $0.00 | $0.00 |
| TOTAL | N/A | $1,016,350.00 | $1,067,168.00 |
| ( 13 -24 Months ) | | | | |
| Labor Position(s) | Labor Hours | No of FTEs | Hourly Rate | Total Price |
| Example: Scientist | 1,980 | 1 | $68.50 | $142,411.50 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| TOTAL | 1980 | 1.00 | N/A | $142,411.50 |
| Other Direct Costs (ODCs) | | | |
| ODCs | Quantity | Price ($) | Total |
| Example: Subcontractor (XXXXXX) | 25 | $65.00 | $1,706.25 |
| Example: Consultant (Sarah Smith) | 31 | $10,850.00 | $353,167.50 |
| Example: Travel/Trip #3 | 1 | $4,000.00 | $4,000.00 |
| | $0.00 | $ |
| | $0.00 | $ |
| | | $ |
| TOTAL | N/A | N/A | $358,873.75 |
| Total Price ($) |
| Objective 1 (1-12 mns) Labor | $0.00 |
| Objective 1 (1-12 mns) ODCs | $0.00 |
| Objective 1 (13 -24) Labor | $0.00 |
| Objective 1 (13 - 24) ODCs | $0.00 |
| Price |
| Objective 1 - Labor (FFP) | $0 |
| Objective 1 - ODCs (Cost only) | $0 |
| TOTAL: | $0 |
Objective 2-FFP
| OBJECTIVE 2 - 24 MONTHS | | | | | |
| | | | | ( 1-12 Months ) | |
| Labor Position(s) | | | | | |
| Sult, Christopher M CIV USARMY USAMRAA (USA): Labor for the Prime Performer only. | Labor Hours | No of FTEs | Hourly Rate | Total Hourly Rate | | |
| Example: Scientist | | 1,980 | 1 | $50.00 | |
| 1374798916: Propose in US Dollars and round to the the hundreth decimal place in every cell. | $99,000.00 | | | | | |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| TOTAL | | 1980 | 1 | N/A | N/A |
| Other Direct Costs (ODCs) | | | |
| ODCs | Quantity | Price ($) | Total |
| Example: Subcontractor (ABC Inc.) | N/A | $1,000,000.00 | $1,050,000.00 |
| Example: Consultant (Sarah Smith) | 31 hrs | $10,850.00 | $11,393.00 |
| Example: Travel/Trip #1 | 1 | $3,500.00 | $3,675.00 |
| Example: Travel/Trip #2 | 1 | $2,000.00 | $2,100.00 |
| | $0.00 | $0.00 |
| | $0.00 | $0.00 |
| TOTAL | N/A | $1,016,350.00 | $1,067,168.00 |
| ( 13 -24 Months ) | | | | |
| Labor Position(s) | Labor Hours | No of FTEs | Hourly Rate | Total Price |
| Example: Scientist | 1,980 | 1 | $68.50 | $142,411.50 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| TOTAL | 1980 | 1.00 | N/A | $142,411.50 |
| Other Direct Costs (ODCs) | | | |
| ODCs | Quantity | Price ($) | Total |
| Example: Subcontractor (XXXXXX) | 25 | $65.00 | $1,706.25 |
| Example: Consultant (Sarah Smith) | 31 | $10,850.00 | $353,167.50 |
| Example: Travel/Trip #3 | 1 | $4,000.00 | $4,000.00 |
| | $0.00 | $ |
| | $0.00 | $ |
| | | $ |
| TOTAL | N/A | N/A | $358,873.75 |
| Total Price ($) |
| Objective 2 (1 -12 mns) Labor | $0.00 |
| Objective 2 ( 1-12 mns) ODCs | $0.00 |
| Objective 2 (13 - 24 mns) Labor | $0.00 |
| Objective 2 (13 - 24 mns) ODCs | $0.00 |
| Price |
| Objective 2 - Labor (FFP) | $0 |
| Objective 2 - ODCs (Cost only) | $0 |
| TOTAL: | $0 |
Objective 3-FFP
| OBJECTIVE 3 - 6 MONTHS | | | | | |
| (6 Months ) | | | | | |
| Labor Position(s) | | | | | |
| Sult, Christopher M CIV USARMY USAMRAA (USA): Labor for the Prime Performer only. | Labor Hours | No of FTEs | Hourly Rate | Total Hourly Rate | | |
| Example: Scientist | | 1,980 | 1 | $50.00 | |
| 1374798916: Propose in US Dollars and round to the the hundreth decimal place in every cell. | $99,000.00 | | | | | |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| TOTAL | | 1980 | 1 | N/A | N/A |
| Other Direct Costs (ODCs) | | | |
| ODCs | Quantity | Price ($) | Total |
| Example: Subcontractor (ABC Inc.) | N/A | $1,000,000.00 | $1,050,000.00 |
| Example: Consultant (Sarah Smith) | 31 hrs | $10,850.00 | $11,393.00 |
| Example: Travel/Trip #1 | 1 | $3,500.00 | $3,675.00 |
| Example: Travel/Trip #2 | 1 | $2,000.00 | $2,100.00 |
| | $0.00 | $0.00 |
| | $0.00 | $0.00 |
| TOTAL | N/A | $1,016,350.00 | $1,067,168.00 |
| Total Price ($) |
| Objective 3 ( 6 mns ) Labor | $0.00 |
| Objective 3 - (6 mns) ODCs | $0.00 |
| Price |
| Objective 3 - Labor (CPFF) | $0 |
| Objective 3 - ODCs (Cost only) | $0 |
| TOTAL: | $0 |
ODC - Consultant(s)
| Consultant ODC Cost | | | | | |
| Labor Position(s) | Labor Hours | Hourl Rate | Cost | G&A | Total Cost |
| Dr. Sarah Smith | 31 | $350.00 | $10,850.00 | $543.00 | $11,393.00 |
| | $0.00 | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 | $0.00 |
| Total: | | | | | $11,393.00 |
ODC - Material & Supplies
| ODCs - Materials and Supplies | | | | |
| Materials and Supplies | Quantity | Unit Cost | G&A | Total Cost |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| TOTAL | | | $0.00 |
TOTAL $ - 0 $ - 0
ODC - General
| ODCs - General | | | | |
| General ODCs | Quantity | Unit Cost | G&A | Total Cost |
| Clinical Trial Insurance / Indemtification Insurance | 1 | $80,000.00 | $8,000.00 | $88,000.00 |
| FDA Application Fee | 1 | $4,682,003.00 | $468,200.30 | $5,150,203.30 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| | $0.00 | $0.00 | $0.00 |
| Total | N/A | $ - 0 | $ | $ |
ODC - Travel
| ODCs - Travel | | | | | | | | | | | | | | |
| Trip | Purpose | Origin | Destination | Duration (days) | Airfare | Accom's | Meals & Incidental | Per Person Subtotal | # of Travellers | SubTotal | Car rental | Trip Subtotal | G&A | Total |
| 1 | | | | | | | | | | | | | | |
| 2 | | | | | | | | | | | | | | |
| 3 | | | | | | | | | | | | | | |
| 4 | | | | | | | | | | | | | | |
| 5 | | | | | | | | | | | | | | |
| 6 | | | | | | | | | | | | | | |
| 7 | | | | | | | | | | | | | | |
| 8 | | | | | | | | | | | | | | |
| 9 | | | | | | | | | | | | | | |
| 10 | | | | | | | | | | | | | | |
| 11 | | | | | | | | | | | | | | |
| 12 | | | | | | | | | | | | | | |
| 13 | | | | | | | | | | | | | | |
| 14 | | | | | | | | | | | | | | |
| 15 | | | | | | | | | | | | | | |
| 16 | | | | | | | | | | | | | | |
| 17 | | | | | | | | | | | | | | |
| 18 | | | | | | | | | | | | | | |
| 19 | | | | | | | | | | | | | | |
| 20 | | | | | | | | | | | | | | |
| 21 | | | | | | | | | | | | | | |
| 22 | | | | | | | | | | | | | | |
| 23 | | | | | | | | | | | | | | |
| 24 | | | | | | | | | | | | | | |
| 25 | | | | | | | | | | | | | | |
| 26 | | | | | | | | | | | | | | |
| 27 | | | | | | | | | | | | | | |
| | | | | | | | | Total | | | | | $0.00 |
ODCs - Subcontractors
| Name of Subcontractor: | XXXXXX | | | | |
| Service provided: | XXXXXX | | | | |
| OBJECTIVES 1 / 24 MONTHS | | | | | |
| ( 1-12 Months ) | | | | | |
| Subcontractor Labor Position(s) | | | | | |
| Sult, Christopher M CIV USARMY USAMRAA (USA): Labor for the Subcontractor only. | Labor Hours | No of FTEs | Hourly Rate | Total Hourly Rate | | |
| Example: Scientist | | 1,980 | 1 | $50.00 | |
| 1374798916: Propose in US Dollars and round to the the hundreth decimal place in every cell. | $99,000.00 | | | | | |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| | | | | $0.00 | $0.00 |
| TOTAL | | 1980 | 1 | N/A | $ 99,000.00 |
| Other Direct Costs (ODCs) | | | |
| ODCs | Quantity | Price ($) | Total |
| Example: materials/supplies for XXXXX | 25 | $1,000.00 | $25,000.00 |
| | $0.00 | $0.00 |
| | $0.00 | $0.00 |
| TOTAL | N/A | | $25,000.00 |
| ( 13 - 24 Months ) | | | | |
| Subcontractor Labor Position(s) | Labor Hours | No of FTEs | Hourly Rate | Total Price |
| Example: Scientist | 1,980 | 1 | $68.50 | $142,411.50 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| TOTAL | 1980 | 1.00 | N/A | $142,411.50 |
| Other Direct Costs (ODCs) | | | |
| ODCs | Quantity | Price ($) | Total |
| Example: Materials/supplies | 25 | $1,000.00 | $25,000.00 |
TOTAL N/A N/A $25,000.00
| OBJECTIVE 2 - 24 MONTHS | | | | |
| ( 13 -24 Months ) | | | | |
| Labor | | | | |
| Subcontractor Labor Position(s) | Labor Hours | No of FTEs | Hourly Rate | Total Hourly Rate |
| Example: Scientist | 1,980 | 1 | $50.00 | $99,000.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| TOTAL | 1980 | 1 | N/A | N/A |
| Other Direct Costs (ODCs) | | | |
| ODCs | Quantity | Price ($) | Total |
| Example: Materials/supplies | 25 | $1,000.00 | $25,000.00 |
TOTAL N/A $25,000.00
| ( 13 -24 Months ) | | | | |
| Labor | | | | |
| Labor Position(s) | Labor Hours | No of FTEs | Hourly Rate | Total Price |
| Example: Scientist | 1,980 | 1 | $68.50 | $142,411.50 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| TOTAL | 1980 | 1.00 | N/A | $142,411.50 |
| Other Direct Costs (ODCs) | | | |
| ODCs | Quantity | Price ($) | Total |
| Example: Materials/supplies | 25 | $1,000.00 | $25,000.00 |
| OBJECTIVE 3 - 6 MONTHS | | | | |
| (6 Months ) | | | | |
| Subcontractor Labor Position(s) | Labor Hours | No of FTEs | Hourly Rate | Total Hourly Rate |
| Example: Scientist | 1,980 | 1 | $50.00 | $99,000.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| | | $0.00 | $0.00 |
| TOTAL | 1980 | 1 | N/A | N/A |
| Other Direct Costs (ODCs) | | | |
| ODCs | Quantity | Price ($) | Total |
| Example: Materials/supplies | 25 | $1,000.00 | $25,000.00 |
| TOTAL | | N/A | N/A | $25,000.00 |
| Total Price ($) | | | |
| Objective 1 (1-12 mns) Labor | $0.00 | | | |
| Objective 1 (1-12 mns) ODCs | $0.00 | | | |
| Objective 1 (13 -24) Labor | $0.00 | | | |
| Objective 1 (13 - 24) ODCs | $0.00 | | | |
| Price |
| Objective 1 - Labor (FFP) | $0 |
| Objective 1 - ODCs (Cost only) | $0 |
| TOTAL: | $0 |
| Total Price ($) |
| Objective 2 (1 -12 mns) Labor | $0.00 |
| Objective 2 ( 1-12 mns) ODCs | $0.00 |
| Objective 2 (13 - 24 mns) Labor | $0.00 |
| Objective 2 (13 - 24 mns) ODCs | $0.00 |
| Price |
| Objective 2 - Labor (FFP) | $0 |
| Objective 2 - ODCs (Cost only) | $0 |
| TOTAL: | $0 |
| Total Price ($) |
| Objective 3 ( 6 mns ) Labor | $0.00 |
| Objective 3 - (6 mns) ODCs | $0.00 |
| Price |
| Objective 3 - Labor (CPFF) | $0 |
| Objective 3 - ODCs (Cost only) | $0 |
| TOTAL: | $0 |
Fringe G&A Fee
| Labor | Non-Labor |
| G&A Rate: | 15% | 10% |
| Fringe Rate: | | |
| Fee: | 7.5% | 0.0% |
Project Personnel v3
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 66.30% | | | | | | 100.00% | | | | | | 100.00% | | | | | 33.70% | | | |
| | | | | | | | | | | | | | | | | | | | | | | Project Total | | | | | | Year Ending September 30, 2026 | | | | | | Year Ending September 30, 2027 | | | | | | Year Ending September 30, 2028 | | | | | Year Ending September 30, 2029 | | | |
| | Name | % | CUR | FX | annual | Hours in Year | Labor Position(s) | "Prime" or "Sub" | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sult, Christopher M CIV USARMY USAMRAA (USA): Please list labor for the Prime Performer then any Sub Performers. | Labor Hours | No of FTEs | Unburdened hourly rate ($) | Fringe ($) | Overhead ($) | Labor G&A ($) | Fee | Fully Burdened Hourly Rate (Cost) ($) | | Cost ($) | Fixed Fee ($) | TOTAL (Cost + FF) | | % | Hours | Cost ($) | Fixed Fee ($) | TOTAL (Cost + FF) | | % | Hours | Cost ($) | Fixed Fee ($) | TOTAL (Cost + FF) | | % | Hours | Cost ($) | Fixed Fee ($) | TOTAL (Cost + FF) | | % | Hours | Cost ($) | Fixed Fee ($) | TOTAL (Cost + FF) | | % | Hours | Cost ($) | Fixed Fee ($) | TOTAL (Cost + FF) | | | | | | | |
| Program Director-Eddy Lee | Eddy Lee | 20% | SGD | 0.7800 | 463,500 | 1,880 | Program Director | | 376 | 0.20 | $192.30 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1374798916: Please propose in US Dollars and round to the the hundreth decimal place in every cell. | | $0.00 | $28.85 | $22.12 | $221.15 | | $83,152.40 | $8,317.12 | $91,469.52 | | 20% | 1,128 | $249,457.20 | $24,951.36 | $274,408.56 | | 20% | 249 | $55,066.35 | $5,507.88 | $60,574.23 | | 20% | 376 | $83,152.40 | $8,317.12 | $91,469.52 | | 20% | 376 | $83,152.40 | $8,317.12 | $91,469.52 | | 20% | 127 | $28,086.05 | $2,809.24 | $30,895.29 | | | | | | | | | | |
| Administrative Assistant-Sarah Chan | Sarah Chan | 40% | SGD | 0.7800 | 108,000 | 1,880 | Administrative Assistant | | 752 | 0.40 | $44.81 | | $0.00 | $6.72 | $5.15 | $51.53 | | $38,750.56 | $3,872.80 | $42,623.36 | | 40% | 2,256 | $116,251.68 | $11,618.40 | $127,870.08 | | 40% | 499 | $25,713.47 | $2,569.85 | $28,283.32 | | 40% | 752 | $38,750.56 | $3,872.80 | $42,623.36 | | 40% | 752 | $38,750.56 | $3,872.80 | $42,623.36 | 40% | 253 | $13,037.09 | $1,302.95 |
| Project Manager-Eva Tan | Eva Tan | 20% | SGD | 0.7800 | 230,000 | 1,880 | Project Manager | | 376 | 0.20 | $95.43 | | $0.00 | $14.31 | $10.97 | $109.74 | | $41,262.24 | $4,124.72 | $45,386.96 | | 20% | 1,128 | $123,786.72 | $12,374.16 | $136,160.88 | | 20% | 249 | $27,325.26 | $2,731.53 | $30,056.79 | | 20% | 376 | $41,262.24 | $4,124.72 | $45,386.96 | | 20% | 376 | $41,262.24 | $4,124.72 | $45,386.96 | 20% | 127 | $13,936.98 | $1,393.19 |
| Project Manager - US-TBH | TBH | 100% | USD | 1.0000 | 140,000 | 1,880 | Project Manager - US | | 1,880 | 1.00 | $74.47 | | $0.00 | $11.17 | $8.56 | $85.64 | | $161,003.20 | $16,092.80 | $177,096.00 | | 100% | 5,640 | $483,009.60 | $48,278.40 | $531,288.00 | | 100% | 1,246 | $106,707.44 | $10,665.76 | $117,373.20 | | 100% | 1,880 | $161,003.20 | $16,092.80 | $177,096.00 | | 100% | 1,880 | $161,003.20 | $16,092.80 | $177,096.00 | 100% | 634 | $54,295.76 | $5,427.04 |
| Product Deveopment Lead-J Krishnarajah | J Krishnarajah | 70% | SGD | 0.7800 | 486,000 | 1,880 | Product Deveopment Lead | | 1,316 | 0.70 | $201.64 | | $0.00 | $30.25 | $23.19 | $231.89 | | $305,167.24 | $30,518.04 | $335,685.28 | | 70% | 3,927 | $910,632.03 | $91,067.13 | $1,001,699.16 | | 90% | 1,040 | $241,165.60 | $24,117.60 | $265,283.20 | | 69% | 1,290 | $299,138.10 | $29,915.10 | $329,053.20 | | 62% | 1,167 | $270,615.63 | $27,062.73 | $297,678.36 | 68% | 430 | $99,712.70 | $9,971.70 |
| Senior Clinical Trial Manager-TBH | TBH | 100% | USD | 1.0000 | 200,000 | 1,880 | Senior Clinical Trial Manager | | 1,880 | 1.00 | $106.38 | | $0.00 | $15.96 | $12.23 | $122.34 | | $229,999.20 | $22,992.40 | $252,991.60 | | 100% | 5,640 | $689,997.60 | $68,977.20 | $758,974.80 | | 100% | 1,246 | $152,435.64 | $15,238.58 | $167,674.22 | | 100% | 1,880 | $229,999.20 | $22,992.40 | $252,991.60 | | 100% | 1,880 | $229,999.20 | $22,992.40 | $252,991.60 | 100% | 634 | $77,563.56 | $7,753.82 |
| CMC/ Manufacturing Manager-Alan Thomson | Alan Thomson | 20% | AUD | 0.6800 | 190,962 | 1,880 | CMC/ Manufacturing Manager | | 376 | 0.20 | $69.07 | | $0.00 | $10.36 | $7.94 | $79.43 | | $29,865.68 | $2,985.44 | $32,851.12 | | 20% | 1,128 | $89,597.04 | $8,956.32 | $98,553.36 | | 40% | 499 | $39,635.57 | $3,962.06 | $43,597.63 | | 10% | 188 | $14,932.84 | $1,492.72 | $16,425.56 | | 10% | 188 | $14,932.84 | $1,492.72 | $16,425.56 | 40% | 253 | $20,095.79 | $2,008.82 |
| Quality Assurance Manager-Cornelia Gallautz | Cornelia Gallautz | 10% | AUD | 0.6800 | 128,750 | 1,880 | Quality Assurance Manager | | 188 | 0.10 | $46.57 | | $0.00 | $6.99 | $5.36 | $53.56 | | $10,069.28 | $1,007.68 | $11,076.96 | | 10% | 564 | $30,207.84 | $3,023.04 | $33,230.88 | | 20% | 249 | $13,336.44 | $1,334.64 | $14,671.08 | | 5% | 94 | $5,034.64 | $503.84 | $5,538.48 | | 5% | 94 | $5,034.64 | $503.84 | $5,538.48 | 20% | 127 | $6,802.12 | $680.72 |
| Quality Assurance- Snr Associate-Veronika Podolsky | Veronika Podolsky | 10% | AUD | 0.6800 | 103,000 | 1,880 | Quality Assurance- Snr Associate | | 188 | 0.10 | $37.26 | | $0.00 | $5.59 | $4.29 | $42.85 | | $8,055.80 | $806.52 | $8,862.32 | | 10% | 564 | $24,167.40 | $2,419.56 | $26,586.96 | | 20% | 249 | $10,669.65 | $1,068.21 | $11,737.86 | | 5% | 94 | $4,027.90 | $403.26 | $4,431.16 | | 5% | 94 | $4,027.90 | $403.26 | $4,431.16 | 20% | 127 | $5,441.95 | $544.83 |
| Analytical Scientist 1-Neil Choi | Neil Choi | 10% | AUD | 0.6800 | 130,000 | 1,880 | Analytical Scientist 1 | | 188 | 0.10 | $47.02 | | $0.00 | $7.05 | $5.41 | $54.07 | | $10,165.16 | $1,017.08 | $11,182.24 | | 10% | 564 | $30,495.48 | $3,051.24 | $33,546.72 | | 20% | 249 | $13,463.43 | $1,347.09 | $14,810.52 | | 5% | 94 | $5,082.58 | $508.54 | $5,591.12 | | 5% | 94 | $5,082.58 | $508.54 | $5,591.12 | 20% | 127 | $6,866.89 | $687.07 |
| Analytical Scientist 2-Lin Yang | Lin Yang | 10% | AUD | 0.6800 | 108,150 | 1,880 | Analytical Scientist 2 | | 188 | 0.10 | $39.12 | | $0.00 | $5.87 | $4.50 | $44.99 | | $8,458.12 | $846.00 | $9,304.12 | | 10% | 564 | $25,374.36 | $2,538.00 | $27,912.36 | | 20% | 249 | $11,202.51 | $1,120.50 | $12,323.01 | | 5% | 94 | $4,229.06 | $423.00 | $4,652.06 | | 5% | 94 | $4,229.06 | $423.00 | $4,652.06 | 20% | 127 | $5,713.73 | $571.50 |
| Finance Manager-Chew Sien Lup | Chew Sien Lup | 20% | SGD | 0.7800 | 247,200 | 1,880 | Finance Manager | | 376 | 0.20 | $102.56 | | $0.00 | $15.38 | $11.79 | $117.94 | | $44,345.44 | $4,433.04 | $48,778.48 | | 20% | 1,127 | $132,918.38 | $13,287.33 | $146,205.71 | | 35% | 436 | $51,421.84 | $5,140.44 | $56,562.28 | | 15% | 282 | $33,259.08 | $3,324.78 | $36,583.86 | | 15% | 282 | $33,259.08 | $3,324.78 | $36,583.86 | 20% | 127 | $14,978.38 | $1,497.33 |
| Finance Accountant-Elena Ling | Elena Ling | 50% | SGD | 0.7800 | 84,000 | 1,880 | Finance Accountant | | 940 | 0.50 | $34.85 | | $0.00 | $5.23 | $4.01 | $40.08 | | $37,675.20 | $3,769.40 | $41,444.60 | | 50% | 2,820 | $113,025.60 | $11,308.20 | $124,333.80 | | 50% | 623 | $24,969.84 | $2,498.23 | $27,468.07 | | 50% | 940 | $37,675.20 | $3,769.40 | $41,444.60 | | 50% | 940 | $37,675.20 | $3,769.40 | $41,444.60 | 50% | 317 | $12,705.36 | $1,271.17 |
| Manufacturing Operator 1-Nigel Morel | Nigel Morel | | AUD | 0.6800 | 93,453 | 1,880 | Manufacturing Operator 1 | | 0 | 0.00 | $33.80 | | $0.00 | $5.07 | $3.89 | $38.87 | | $0.00 | $0.00 | $0.00 | | 0% | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | 0 | $0.00 | $0.00 |
| Manufacturing Operator 2-Francis Orbien | Francis Orbien | | AUD | 0.6800 | 87,570 | 1,880 | Manufacturing Operator 2 | | 0 | 0.00 | $31.67 | | $0.00 | $4.75 | $3.64 | $36.42 | | $0.00 | $0.00 | $0.00 | | 0% | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | 0 | $0.00 | $0.00 |
| Procurement & Logistic Manager-Jeremy Dalton | Jeremy Dalton | | AUD | 0.6800 | 243,904 | 1,880 | Procurement & Logistic Manager | | 0 | 0.00 | $88.22 | | $0.00 | $13.23 | $10.15 | $101.45 | | $0.00 | $0.00 | $0.00 | | 0% | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | 0 | $0.00 | $0.00 |
| Snr Clinical Quality Assurance Manager-TBH | TBH | 55% | USD | 1.0000 | 200,000 | 1,880 | Snr Clinical Quality Assurance Manager | | 1,034 | 0.55 | $106.38 | | $15.96 | $18.35 | $14.07 | $140.69 | | $145,473.46 | $14,548.38 | $160,021.84 | | 55.0% | 3,102 | $386,912.46 | $43,645.14 | $430,557.60 | | 60% | 748 | $93,298.04 | $10,524.36 | $103,822.40 | | 60% | 1,128 | $140,695.44 | $15,870.96 | $156,566.40 | | 45% | 846 | $105,521.58 | $11,903.22 | $117,424.80 | 60% | 380 | $47,397.40 | $5,346.60 |
| | | | | | | | | | 0 | 0.00 | $0.00 | | $0.00 | $0.00 | $0.00 | $0.00 | | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | 0 | $0.00 | $0.00 |
| | | | | | | | | | 0 | 0.00 | $0.00 | | $0.00 | $0.00 | $0.00 | $0.00 | | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | | 0 | $0.00 | $0.00 | $0.00 | | 0 | $0.00 | $0.00 |
| | | | | | | | TOTAL | N/A | 10058.00 | 5.35 | N/A | $0.00 | $15.96 | $205.13 | | N/A | | $1,153,442.98 | $115,331.42 | $1,268,774.40 | | | | $3,405,833.39 | $345,495.48 | $3,751,328.87 | | | | $866,411.08 | $87,826.73 | $954,237.81 | | | | $1,098,242.44 | $111,611.44 | $1,209,853.88 | | | | $1,034,546.11 | $104,791.33 | $1,139,337.44 | | | $406,633.76 | $41,265.98 |
| Consultants | | | | | | | | | | | | | |
| 40% | 1.0000 | 300,000 | | RegulatoryAffair | 792 | 0.40 | $350.00 | $35.00 | $350.00 | $277,200.00 | $27,720.00 | $304,920.00 |
| 100% | 1 | 333333.333333333 | 1980 | BDO | 1,980 | 1.00 | $168.35 | $16.84 | $168.35 | $333,333.00 | $33,343.20 | $366,676.20 |
$1,763,975.98 $176,394.62 $1,940,370.60
3 years $5,821,111.80
| Supply of Investigative Products | $67,500.00 |
| Validation & stability | $225,000.00 |
| Vendor Quality Audit | $150,000.00 |
| PV consultant | $90,000.00 |
$6,353,611.80
Timeline v3
| | | | | | | | | M2 | M3 | M7 | M13 | M15 | M16 | M18 | | M19 | M20 | M22 | M22 | M25 | M27 | M31 | M34 | M35 | M35 | M39 | M39 | | M40 | M43 | M43 | M44 | M44 | M45 | M46 | M48 | M48 | M50 | M50 | M50 | | M50 | M50 | M52 | M52 | ??? | |
| | | | | | | | | M2 | M3 | M7 | M13 | M15 | M16 | M18 | | M19 | M20 | M22 | M22 | M25 | M27 | M31 | M34 | M35 | M35 | M39 | M39 | | M40 | M43 | M43 | M44 | M44 | M45 | M46 | M48 | M48 | M50 | M50 | M50 | | M50 | M50 | M52 | M52 | ??? | |
| | | | | | Gov FY Year | | | 2026 | 2026 | 2026 | 2026 | 2026 | 2026 | 2026 | | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 | | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 | | 2029 | 2029 | 2029 | 2029 | 2029 | |
| | | | | | Calendar Year | 2026 | 2026 | 2026 | 2026 | 2026 | 2026 | 2026 | 2026 | 2026 | 2026 Gov Total | 2026 | 2026 | 2026 | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 | 2027 Total | 2027 | 2027 | 2027 | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 | 2028 Total | 2028 | 2028 | 2028 | 2029 | 2029 | 2028 Total |
| Objective | Item | Start | Finish | % | Labor Position | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| & Name | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Total | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Total | Oct | Nov | Dec | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Total | Oct | Nov | Dec | Jan | Feb | Total | | | | | | |
| 2 | KET-004 | 1-Feb-26 | 31-Aug-26 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | Dog Tox Study | 15-May-26 | 15-Sep-26 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | Pharmetheus | 15-Jun-26 | 31-Jul-26 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | Submit Ph3 protocol to FDA | 1-Oct-26 | 1-Oct-26 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | KET-006 | 1-Dec-26 | 31-May-28 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | KET-007 | 1-Feb-27 | 31-Mar-28 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | KET-013 | 1-Nov-26 | 15-Jun-27 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | KET-014 | 1-Dec-26 | 15-Jul-27 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | NDA Filing | 1-Dec-28 | 31-Dec-28 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4 | EUA | 1-Feb-26 | 31-Jan-27 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Janakan's time allocation 3,948
| 2 | KET-004 | 1-Mar-26 | 31-Aug-26 | 3.00% |
| 2 | Dog Tox Study | 15-May-26 | 15-Sep-26 | 5.00% |
| 2 | Pharmetheus | 15-Jun-26 | 31-Jul-26 | 2.00% |
| 3 | Submit Ph3 protocol to FDA | 1-Apr-26 | 1-Oct-26 | 7.00% |
| 3 | KET-006 | 1-Dec-26 | 31-May-28 | 15.00% |
| 3 | KET-007 | 1-Mar-27 | 31-Mar-28 | 15.00% |
| 3 | KET-013 | 1-Nov-26 | 15-Jun-27 | 3.00% |
| 3 | KET-014 | 1-Dec-26 | 15-Jul-27 | 5.00% |
| 1 | NDA Filing (& preparation) | 1-Jun-28 | 31-Dec-28 | 20.00% |
| 4 | EUA | 1-Mar-26 | 31-Jan-27 | 10.00% |
| General/CMC | 1-Mar-26 | 31-Jan-29 | 15.00% |
| | | | 100.00% |
| 2 | KET-004 | 1-Mar-26 | 31-Aug-26 | 118 | J Krishnarajah | 0 | 0 | 19 | 19 | 20 | 19 | 20 | 20 | 0 | 117 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | Dog Tox Study | 15-May-26 | 15-Sep-26 | 197 | J Krishnarajah | 0 | 0 | 0 | 0 | 26 | 48 | 50 | 50 | 0 | 174 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | Pharmetheus | 15-Jun-26 | 31-Jul-26 | 79 | J Krishnarajah | 0 | 0 | 0 | 0 | 0 | 26 | 53 | 0 | 0 | 79 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | Submit Ph3 protocol to FDA | 1-Apr-26 | 1-Oct-26 | 276 | J Krishnarajah | 0 | 0 | 0 | 44 | 47 | 45 | 47 | 47 | 45 | 275 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | KET-006 | 1-Dec-26 | 31-May-28 | 592 | J Krishnarajah | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 34 | 30 | 34 | 32 | 34 | 32 | 34 | 34 | 32 | 328 | 34 | 32 | 34 | 34 | 31 | 34 | 32 | 34 | 0 | 0 | 0 | 0 | 265 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | KET-007 | 1-Mar-27 | 31-Mar-28 | 592 | J Krishnarajah | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 45 | 45 | 46 | 45 | 46 | 46 | 45 | 318 | 46 | 45 | 46 | 46 | 43 | 46 | 0 | 0 | 0 | 0 | 0 | 0 | 272 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | KET-013 | 1-Nov-26 | 15-Jun-27 | 118 | J Krishnarajah | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 16 | 16 | 15 | 16 | 16 | 16 | 0 | 0 | 0 | 0 | 110 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | KET-014 | 1-Dec-26 | 15-Jul-27 | 197 | J Krishnarajah | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 27 | 24 | 27 | 26 | 27 | 26 | 0 | 0 | 0 | 183 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | NDA Filing (& preparation) | 1-Jun-28 | 31-Dec-28 | 790 | J Krishnarajah | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 108 | 115 | 115 | 111 | 449 | 115 | 111 | 115 | 0 | 0 | 341 |
| 4 | EUA | 1-Mar-26 | 31-Jan-27 | 395 | J Krishnarajah | 0 | 0 | 35 | 35 | 36 | 35 | 36 | 36 | 35 | 248 | 36 | 35 | 36 | 36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 143 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | General/CMC | 1-Mar-26 | 31-Jan-29 | 592 | J Krishnarajah | 0 | 0 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 119 | 17 | 17 | 17 | 17 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 203 | 17 | 17 | 17 | 17 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 203 | 23 | 23 | 23 | 23 | 0 | 90 |
| 3,946 | 0 | 71 | 115 | 146 | 190 | 223 | 170 | 97 | 53 | 67 | 127 | 130 | 85 | 139 | 136 | 140 | 120 | 97 | 97 | 94 | 97 | 94 | 97 | 97 | 90 | 97 | 49 | 51 | 125 | 132 | 132 | 128 | 138 | 134 | 138 | 23 | 0 |
| | | | | | | | | 1012 | | | | | | | | | | | | 1,285.0 | | | | | | | | | | | | 1,189.0 | | | | 431.0 | |
| Project Manager - US - time allocation | 5,664 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | KET-004 | 1-Mar-26 | 31-Aug-26 | 2.47% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | Dog Tox Study | 15-May-26 | 15-Sep-26 | 4.12% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | Pharmetheus | 15-Jun-26 | 31-Jul-26 | 1.65% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | Submit Ph3 protocol to FDA | 1-Apr-26 | 1-Oct-26 | 5.76% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | KET-006 | 1-Dec-26 | 31-May-28 | 12.35% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | KET-007 | 1-Mar-27 | 31-Mar-28 | 12.35% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | KET-013 | 1-Nov-26 | 31-Mar-27 | 2.47% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | KET-014 | 1-Dec-26 | 30-Apr-27 | 4.12% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | NDA Filing (& preparation) | 1-Jun-28 | 31-Dec-28 | 16.47% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 4 | EUA | 1-Mar-26 | 31-Jan-27 | 8.24% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| General/CMC | 1-Mar-26 | 31-Jan-29 | 30.00% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | 100.00% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | Project Manager - US-TBD & Clinical Project Coordinator-TBD | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | KET-004 | 1-Mar-26 | 31-Aug-26 | 140 | X | 0 | 0 | 20 | 20 | 21 | 20 | 21 | 21 | 0 | 122 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | Dog Tox Study | 15-May-26 | 15-Sep-26 | 233 | X | 0 | 0 | 0 | 0 | 26 | 49 | 51 | 51 | 0 | 177 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | Pharmetheus | 15-Jun-26 | 31-Jul-26 | 93 | X | 0 | 0 | 0 | 0 | 0 | 26 | 54 | 0 | 0 | 80 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | Submit Ph3 protocol to FDA | 1-Apr-26 | 1-Oct-26 | 327 | X | 0 | 0 | 0 | 45 | 48 | 47 | 48 | 48 | 47 | 281 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | KET-006 | 1-Dec-26 | 31-May-28 | 700 | X | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38 | 40 | 36 | 40 | 38 | 40 | 38 | 40 | 40 | 38 | 389 | 44 | 42 | 44 | 44 | 41 | 44 | 42 | 44 | 0 | 0 | 0 | 0 | 345 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | KET-007 | 1-Mar-27 | 31-Mar-28 | 700 | X | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53 | 53 | 55 | 53 | 55 | 55 | 53 | 378 | 61 | 58 | 61 | 61 | 56 | 61 | 0 | 0 | 0 | 0 | 0 | 0 | 357 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | KET-013 | 1-Nov-26 | 31-Mar-27 | 140 | X | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27 | 29 | 29 | 26 | 29 | 0 | 0 | 0 | 0 | 0 | 0 | 140 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | KET-014 | 1-Dec-26 | 30-Apr-27 | 233 | X | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 47 | 48 | 43 | 48 | 47 | 0 | 0 | 0 | 0 | 0 | 233 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | NDA Filing (& preparation) | 1-Jun-28 | 31-Dec-28 | 933 | X | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 140 | 150 | 150 | 144 | 584 | 146 | 140 | 146 | 0 | 0 | 431 |
| 4 | EUA | 1-Mar-26 | 31-Jan-27 | 466 | X | 0 | 0 | 36 | 36 | 37 | 36 | 37 | 37 | 36 | 257 | 43 | 42 | 43 | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 171 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | General/CMC | 1-Mar-26 | 31-Jan-29 | 1,699 | X | 0 | 0 | 41 | 41 | 42 | 41 | 42 | 42 | 41 | 293 | 46 | 46 | 46 | 46 | 44 | 49 | 48 | 49 | 48 | 49 | 49 | 48 | 569 | 49 | 49 | 49 | 49 | 49 | 49 | 49 | 49 | 49 | 49 | 49 | 53 | 592 | 52 | 51 | 52 | 52 | 0 | 209 |
| 5,664 | 0 | 98 | 143 | 174 | 219 | 253 | 199 | 124 | 89 | 115 | 203 | 206 | 149 | 219 | 186 | 144 | 139 | 144 | 144 | 139 | 154 | 149 | 154 | 154 | 146 | 154 | 91 | 93 | 189 | 199 | 199 | 197 | 198 | 192 | 198 | 52 | 0 |
| | | | | | | | 1209.6618357488 | | | | | | | | | | | | 1,879.9 | | | | | | | | | | | | 1,877.3 | | | | 640.3 | |
| | | | | | | Total beore adjustment | 1449 | | | | | | | | | | | | 1,885.0 | | | | | | | | | | | | 1,714.0 | | | | 594.0 | |
| | | | | | | | 1252 | | | | | | | | | | | | 1,888.0 | | | | | | | | | | | | 1,888.0 | | | | 636.0 | |
| Time cost | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Rate +G&A/Hr | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Project Manager - US | 85.64 | 0 | 4,810 | 8,658 | 11,248 | 15,243 | 18,055 | 13,393 | 7,104 | 3,688 | 5,919 | 13,467 | 13,724 | 9,007 | 14,582 | 11,837 | 8,149 | 7,806 | 8,149 | 8,149 | 7,806 | 8,962 | 8,584 | 8,962 | 8,962 | 8,301 | 8,962 | 3,585 | 3,773 | 11,980 | 12,829 | 12,829 | 12,358 | 12,471 | 12,012 | 12,471 | 0 | 0 | 337,833 |
| Clinical/ Non Clinical Manager | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| Senior Clinical Manager | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| 1 | CMC/ Manufacturing | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| 1 | Quality Assuarance Manager | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| 1 | Quality Assuarance- Snr Associate | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| 1 | Analytical Scientist 1 | 54.07 | 1,683 | 1,683 | 1,683 | 1,683 | 1,683 | 1,683 | 1,683 | 1,683 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 1,717 | 1,717 | 1,717 | 1,717 | | 30,495 |
| 1 | Analytical Scientist 2 | 44.99 | 1,400 | 1,400 | 1,400 | 1,400 | 1,400 | 1,400 | 1,400 | 1,400 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 352 | 1,428 | 1,428 | 1,428 | 1,428 | | 25,374 |
| G | Project Manager - US | 85.64 | 0 | 3,552 | 3,552 | 3,626 | 3,552 | 3,626 | 3,626 | 3,552 | 3,939 | 3,939 | 3,939 | 3,939 | 3,790 | 4,203 | 4,117 | 4,203 | 4,117 | 4,203 | 4,203 | 4,117 | 4,196 | 4,196 | 4,196 | 4,196 | 4,196 | 4,196 | 4,196 | 4,196 | 4,196 | 4,196 | 4,196 | 4,528 | 4,493 | 4,401 | 4,493 | 4,493 | 142,365 |
| G | Senior Clinical Manager | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| G | Program Director | 221.15 | 6,883 | 6,883 | 6,883 | 6,883 | 6,883 | 6,883 | 6,883 | 6,883 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 6,929 | 7,022 | 7,022 | 7,022 | 7,022 | 249,457 |
| G | Administrative Assistant | 51.53 | 3,214 | 3,214 | 3,214 | 3,214 | 3,214 | 3,214 | 3,214 | 3,214 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,229 | 3,259 | 3,259 | 3,259 | 3,259 | 116,252 |
| G | Project Manager | 109.74 | 3,416 | 3,416 | 3,416 | 3,416 | 3,416 | 3,416 | 3,416 | 3,416 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,439 | 3,484 | 3,484 | 3,484 | 3,484 | 123,787 |
| G | Finance / Cost Control | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| G | Finance Accountant | 40.08 | 3,121 | 3,121 | 3,121 | 3,121 | 3,121 | 3,121 | 3,121 | 3,121 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,140 | 3,176 | 3,176 | 3,176 | 3,176 | 113,026 |
| ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| Fixed Fee | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A
ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A
| Direct Labour | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| KET-004 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| Dog Tox Study | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| Pharmetheus | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| Submit Ph3 protocol to FDA | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| KET-006 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| KET-007 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| KET-013 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| KET-014 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| NDA Filing | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| EUA | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| General/CMC | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ERROR:#N/A |
| Subcontract Cost | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| KET-004 | 125929 | 144584 | 139920 | 144584 | 139920 | 144584 | 144584 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 984,105 |
| Dog Tox Study | 0 | 0 | 0 | 65732 | 123246 | 127355 | 127355 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 443,688 |
| Pharmetheus | 0 | 0 | 0 | 0 | 97826 | 202174 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 300,000 |
| Submit Ph3 protocol to FDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| KET-006 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 463262 | 478704 | 432378 | 478704 | 463262 | 478704 | 463262 | 478704 | 478704 | 463262 | 478704 | 463262 | 478704 | 478704 | 447820 | 478704 | 463262 | 478704 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8,446,810 |
| KET-007 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 633261 | 727077 | 703623 | 727077 | 703623 | 727077 | 727077 | 703623 | 727077 | 703623 | 727077 | 727077 | 680169 | 727077 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9,944,538 |
| KET-013 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 140473 | 150160 | 150160 | 135630 | 150160 | 145317 | 150160 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,022,060 |
| KET-014 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 136358 | 140902 | 127267 | 140902 | 136358 | 140902 | 136358 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 959,047 |
| NDA Filing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4800000 | 0 | 4,800,000 |
| EUA | 37088 | 42582 | 41209 | 42582 | 41209 | 42582 | 42582 | 41209 | 42582 | 41209 | 42582 | 42582 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 499,998 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 27,400,246 |
| General & CMC | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| KET-004 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| Dog Tox Study | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| Pharmetheus | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| Submit Ph3 protocol to FDA | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| KET-006 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| KET-007 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| KET-013 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| KET-014 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| NDA Filing | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| EUA | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | | ERROR:#N/A |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ERROR:#N/A |
| Labour + subcon | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| KET-004 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| Dog Tox Study | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| Pharmetheus | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| Submit Ph3 protocol to FDA | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| KET-006 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| KET-007 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| KET-013 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| KET-014 | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| NDA Filing | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
| EUA | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A | ERROR:#N/A |
ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A ERROR:#N/A 0 ERROR:#N/A
This is the start of the file's text. The full file is on GovTribe.